TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Average peak power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average muscle endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Administered anesthetic dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-assessed pain levels
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: redislocation after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: apprehension after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: retear at 6 months
Endpoint domain: Adverse events/effects
Primary endpoint: Development of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Infection after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: 90-day mortality associated with infection
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of claustrophobic events
Endpoint domain: Adverse events/effects
Primary endpoint: Perceived claustrophobia after 7 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ROCK activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral relative bioavailability (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of any stroke
Endpoint domain: Mortality/survival
Primary endpoint: Non-procedure-related myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Transient LES relaxations (TLESRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Potassium level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Symptom interference with activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dyspnea measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in glycated hemoglobin from baseline to week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fasting blood glucose levels at week 26
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and rate of hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: reduction of autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: increase in selenemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of patients experiencing secondary surgical interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median renal survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Median time to absolute neutrophil count (ANC) > 0.5 x 10(9)/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Median time to platelet transfusion independence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: usability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Quality of postoperative recovery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Major Depressive Disorder (MDD)
Endpoint domain: Mortality/survival
Primary endpoint: subsequent graft
Endpoint domain: Mortality/survival
Primary endpoint: biopsy-proven acute rejection
Endpoint domain: Adverse events/effects
Primary endpoint: NYHA classification improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lowering of CPK-MB, AST, LDH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement of S-T segment of ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: focal seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in QIDS-C16 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nausea or vomiting incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in clinical fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction in new morphometric vertebral fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in total hip bone mineral density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: body temperature and heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma levels of cytokines (IFN‐γ, IL‐1β, IL‐2, IL‐4, IL‐5, IL‐6, IL‐8, IL‐10, IL‐12, IL‐13, TNFα)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Referral to local community health center
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Referral to primary physician
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Received home care services one month after ED visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Return visit to the ED
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mean level of high-density-lipoprotein (HDL) cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean LDL/HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Shift of pixel count distribution to a higher grayscale range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dialysate-to-plasma creatinine ratio at 4 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Wrist fracture risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in physical functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Cerebral Perfusion Pressure (CPP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success (IGA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically meaningful improvement in disease severity (IGAxBSA-75)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically relevant improvement in QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in glycated hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Decrease in BUN, creatinine, serum potassium and phosphate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Osteoporosis medication adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: postprandial gastric reflex relaxation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: AUA disease-specific functional status scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Total payments for health care resource
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Information about the regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Information about side effects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Readmission rates at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: Exercise tolerance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic Respiratory Questionnaire (CRQ-SR) results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adiponectin/leptin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: distress tolerance levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lumen response to DCA during HUT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma cholesterol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Weight change after 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak geometric mean concentration of antibody against hepatitis B surface antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: c-IMT (carotid intima-media thickness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: marginal sealing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: water sorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: loss of mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intragastric pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Troponin I serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breast and nipple pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Early postoperative mortality
Endpoint domain: Mortality/survival
Primary endpoint: change in posttraumatic stress severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum metabolic profile changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adipose tissue differentiation pathway changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proinflammatory processes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidence of lymphedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of vulvar infections
Endpoint domain: Adverse events/effects
Primary endpoint: Risk reduction of events
Endpoint domain: Mortality/survival
Primary endpoint: IBS hospitalizations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Perceived benefit of treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global health status (GHS) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Grade 3/4 haematological and non‐haematological toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Survival rate at 2 years
Endpoint domain: Mortality/survival
Primary endpoint: Surface roughness increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microhardness decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Filler dissolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in P-wave duration of > 20 ms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of postoperative AF
Endpoint domain: Mortality/survival
Primary endpoint: Concordance of results with monitoring technologies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean bleeding time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of bleeding time > 10 minutes
Endpoint domain: Adverse events/effects
Primary endpoint: Global brain injury score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Motor performance (Alberta Infant Motor Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean concentration of Tac in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Tac-associated side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Water intake until full
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 1.0 to 2.5-cpm activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 2.5 to 3.75-cpm activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Surgical site infection (SSI) rates
Endpoint domain: Mortality/survival
Primary endpoint: Length of SSI-attributable hospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Dipeptidyl peptidase-4 inhibition levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability (no hypoglycemia reported)
Endpoint domain: Adverse events/effects
Primary endpoint: resumption lag
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival benefit from chemotherapy
Endpoint domain: Mortality/survival
Primary endpoint: Extent and severity of psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of incorrect or phantom perceptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptoms of anxiety (SAS scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Symptoms of depression (SDS scores)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of life (I‐QOL scores)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: risk of exacerbation of chronic obstructive pulmonary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Early virologic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: YMDD mutants emergence
Endpoint domain: Adverse events/effects
Primary endpoint: Adherence to HAART
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV-1 RNA levels <400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRSE within 0.50 D of intended
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-reported harms
Endpoint domain: Adverse events/effects
Primary endpoint: Disease-related events
Endpoint domain: Adverse events/effects
Primary endpoint: bioequivalence of glimepiride formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of LAAM as a treatment for heroin dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean intraoperative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Otalgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: function outcome (ordinal shift of the modified Rankin Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission of menopause-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: earlier discharge
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: prevention of fatal and non-fatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Correct diagnosis success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in leisure engagement and ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: trunk fat increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone mineral density (BMD) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mtDNA increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tracheal intubation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum concentration of clarithromycin (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the time‐concentration curve from 0 to 2 h (AUC0‐2h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impaired non-technical skills (ANTS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Startle potentiation by unpleasant stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of collaborative care for depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End stage renal failure requiring dialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: clinical changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for further instruction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reductions in plaque indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reductions in gingival indices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity of needle insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in total plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart symptom cluster
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seizure worry
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ongoing pregnancy rate per started cycle
Endpoint domain: Mortality/survival
Primary endpoint: Ongoing pregnancy rate per embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: Live birth rate per embryo transfer
Endpoint domain: Mortality/survival
Primary endpoint: offset of sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall mid-term survival rate
Endpoint domain: Mortality/survival
Primary endpoint: cumulative rates of sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Platelet NO production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet O2*- production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet NADH oxidase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of total or partial regression of ascites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: duration of treatment and hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: risk of early relapse
Endpoint domain: Mortality/survival
Primary endpoint: preservation of beta cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: metabolic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SvO2 measurement accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year increase in 16α-OHE1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-year increase in 2-OHE1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of NDP model components implemented
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptive reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eicosapentaenoic acid (EPA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Diarrheal incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of basal cell carcinoma at a new site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Annual rate of basal cell carcinoma formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Elevated serum triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: median consultation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in L value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rehospitalizations for ischemic events or bleeding
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: total cancer coping scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Local bone progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Plaque and Gingival score reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes